Mitsubishi UFJ Asset Management Co. Ltd. Has $33.51 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 8.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,082,578 shares of the company’s stock after purchasing an additional 80,106 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $33,506,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Wellington Management Group LLP boosted its position in Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter valued at $100,939,000. Migdal Insurance & Financial Holdings Ltd. boosted its position in Teva Pharmaceutical Industries by 14.8% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after purchasing an additional 4,820,000 shares during the last quarter. Finally, Polar Capital Holdings Plc acquired a new stake in Teva Pharmaceutical Industries during the third quarter valued at $80,983,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $35.71 on Friday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The stock’s 50-day moving average is $31.28 and its two-hundred day moving average is $29.81. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market cap of $41.06 billion, a P/E ratio of 26.85, a price-to-earnings-growth ratio of 3.45 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insiders Place Their Bets

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $33.64, for a total value of $11,633,048.40. Following the transaction, the executive vice president directly owned 57,478 shares in the company, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,127,018 shares of company stock valued at $37,298,712 in the last ninety days. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.